AbCellera Biologics downgraded by The Benchmark Company
$ABCL
Biotechnology: Pharmaceutical Preparations
Health Care
The Benchmark Company downgraded AbCellera Biologics from Buy to Hold
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/7/2026 | $11.00 | Hold → Buy | The Benchmark Company |
| 5/5/2026 | $7.00 | Overweight | Cantor Fitzgerald |
| 11/7/2025 | $4.00 | Outperform → Market Perform | Leerink Partners |
| 7/7/2025 | $5.00 | Outperform | Leerink Partners |
| 8/20/2024 | Buy → Hold | The Benchmark Company | |
| 2/22/2024 | $9.00 | Hold → Buy | The Benchmark Company |
| 12/5/2023 | $6.00 | Overweight | KeyBanc Capital Markets |
| 11/6/2023 | Buy → Hold | The Benchmark Company |
Issued on behalf of MindWalk Holdings Corp.MindWalk Holdings Corp. (NASDAQ:HYFT) heads into its fourth-quarter and full-year results with fresh index inclusion, an expanded patent estate, and AI-designed programs aimed at two of medicine's biggest frontiers: GLP-1 metabolic health and infectious disease.AUSTIN, Texas, July 15, 2026 /CNW/ -- Equity Insider News Commentary - Artificial intelligence has moved from the edges of drug discovery to its center. The biggest pharmaceutical companies in the world are now racing to design molecules with machine learning rather than trial and error, and the market has begun to reward the names building the infrastructure underneath that shift. MindWalk H
AbCellera (NASDAQ:ABCL) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more. For m
AbCellera (NASDAQ:ABCL) today announced the appointment of Lynn Seely, M.D., to its Board of Directors as an independent director. "Dr. Seely is a respected executive leader with a proven track record of successfully developing new medicines in endocrinology, oncology, and women’s health. I am pleased to welcome her to AbCellera’s Board of Directors and look forward to having her on our team," said Carl Hansen, Ph.D., founder and CEO of AbCellera. Dr. Seely’s experience as a biopharmaceutical executive and board member includes an extensive background in strategic, clinical, and commercial execution, which are highly relevant to AbCellera's work in discovering and developing impactful a
4 - AbCellera Biologics Inc. (0001703057) (Issuer)
3 - AbCellera Biologics Inc. (0001703057) (Issuer)
4 - AbCellera Biologics Inc. (0001703057) (Issuer)
AbCellera (NASDAQ:ABCL) today announced the appointment of Lynn Seely, M.D., to its Board of Directors as an independent director. "Dr. Seely is a respected executive leader with a proven track record of successfully developing new medicines in endocrinology, oncology, and women’s health. I am pleased to welcome her to AbCellera’s Board of Directors and look forward to having her on our team," said Carl Hansen, Ph.D., founder and CEO of AbCellera. Dr. Seely’s experience as a biopharmaceutical executive and board member includes an extensive background in strategic, clinical, and commercial execution, which are highly relevant to AbCellera's work in discovering and developing impactful a
AbCellera (NASDAQ:ABCL) today announced the appointment of Victor Sandor, M.D.C.M, to its Board of Directors as an independent director. "Dr. Sandor is an experienced director and a distinguished medical oncologist with experience in building companies and bringing innovative medicines to patients in need," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "I am pleased to welcome Dr. Sandor to AbCellera's Board of Directors and look forward to working with him." Before its acquisition by Pfizer Inc., Dr. Sandor served as Chief Medical Officer at Array BioPharma Inc. where he successfully secured approval of Braftovi® (encorafenib) and Mektovi® (binimetinib). Prior to joining Array
AbCellera (NASDAQ:ABCL) today announced the appointment of Stephen Quake, D.Phil., to its Board of Directors as an independent director. Dr. Quake is a distinguished scientist, inventor, and entrepreneur who has made foundational contributions across diverse fields, including single molecule biophysics, microfluidics, single cell analysis, genomics, molecular diagnostics, and non-invasive prenatal testing. His work is represented in over 300 publications (h-index of 181) and 80+ patents and patent applications. "We are pleased to welcome Dr. Quake to AbCellera's Board of Directors. His presence reinforces our commitment to excellence in science and technology," said Carl Hansen, Ph.D., fo
8-K - AbCellera Biologics Inc. (0001703057) (Filer)
8-K - AbCellera Biologics Inc. (0001703057) (Filer)
8-K - AbCellera Biologics Inc. (0001703057) (Filer)
The Benchmark Company upgraded AbCellera Biologics from Hold to Buy and set a new price target of $11.00
Cantor Fitzgerald initiated coverage of AbCellera Biologics with a rating of Overweight and set a new price target of $7.00
Leerink Partners downgraded AbCellera Biologics from Outperform to Market Perform and set a new price target of $4.00
4 - AbCellera Biologics Inc. (0001703057) (Issuer)
4 - AbCellera Biologics Inc. (0001703057) (Issuer)
4 - AbCellera Biologics Inc. (0001703057) (Issuer)
Issued on behalf of MindWalk Holdings Corp.MindWalk Holdings Corp. (NASDAQ:HYFT) heads into its fourth-quarter and full-year results with fresh index inclusion, an expanded patent estate, and AI-designed programs aimed at two of medicine's biggest frontiers: GLP-1 metabolic health and infectious disease.AUSTIN, Texas, July 15, 2026 /CNW/ -- Equity Insider News Commentary - Artificial intelligence has moved from the edges of drug discovery to its center. The biggest pharmaceutical companies in the world are now racing to design molecules with machine learning rather than trial and error, and the market has begun to reward the names building the infrastructure underneath that shift. MindWalk H
AbCellera (NASDAQ:ABCL) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more. For m
ABCL635 demonstrated a favorable tolerability profile, with no observed liver toxicity, and achieved potent and sustained reductions in biomarkers of target engagement. Ended Q1 2026 with total available liquidity of approximately $655 million. AbCellera (NASDAQ:ABCL) today announced financial results for the first quarter of 2026 and positive interim results from the Phase 1 portion of its ongoing Phase 1/2 clinical trial of ABCL635. ABCL635 is a potential first-in-class antibody targeting the neurokinin 3 receptor (NK3R) for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. All financial information in this press release is reported in U.S. dol
SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)
SC 13G - AbCellera Biologics Inc. (0001703057) (Subject)
SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)